GSK PLC Sponsored ADR (NYSE:GSK) Given Consensus Recommendation of "Hold" by Brokerages

Shares of GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) have earned an average rating of "Hold" from the ten analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $37.38.

GSK has been the topic of several research reports. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Hsbc Global Res upgraded GSK to a "strong sell" rating in a research report on Monday, April 28th. Finally, BNP Paribas started coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target on the stock.

Institutional Investors Weigh In On GSK

A number of institutional investors have recently modified their holdings of GSK. Kingsview Wealth Management LLC raised its stake in shares of GSK by 1.8% during the 1st quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock worth $590,000 after purchasing an additional 271 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its holdings in GSK by 2.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock worth $389,000 after buying an additional 278 shares during the last quarter. Rehmann Capital Advisory Group raised its position in GSK by 4.6% during the first quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock valued at $248,000 after acquiring an additional 279 shares in the last quarter. First PREMIER Bank lifted its stake in GSK by 6.5% in the first quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock valued at $181,000 after acquiring an additional 286 shares during the last quarter. Finally, Northwest Bank & Trust Co grew its position in GSK by 1.3% in the fourth quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock worth $765,000 after acquiring an additional 289 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Stock Down 0.5%

GSK opened at $38.38 on Tuesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87. The company has a market capitalization of $78.58 billion, a PE ratio of 19.78, a P/E/G ratio of 1.35 and a beta of 0.52. The stock's fifty day moving average is $38.90 and its 200-day moving average is $37.00. GSK has a one year low of $31.72 and a one year high of $44.67.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a net margin of 9.89% and a return on equity of 48.82%. GSK's revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.43 EPS. On average, equities analysts predict that GSK will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a $0.4216 dividend. This represents a $1.69 annualized dividend and a yield of 4.39%. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is currently 87.11%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.